It is the first CLDN18.2-targeted drug to market in the US, leading a large pack of would-be competitors. “This is an exciting time for gastric cancer,” says Pranob Bhattacharya, Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback